Tectonic Therapeutic, Inc. (NASDAQ:TECX) is highlighted as one of the Best Micro-Cap Stocks to Invest in According to Analysts. LifeSci Capital reaffirmed a Buy rating on TECX stock with a price target of $88, focusing on the company’s development of therapeutic proteins and antibodies to modulate G protein-coupled receptors.

TECX utilizes the GEODe technology platform for biologic medicines targeting G protein-coupled receptors. Lead product candidate TX45 activates the RXFP1 receptor, while TX2100 treats hereditary hemorrhagic telangiectasia. Despite TECX’s potential, some analysts suggest other AI stocks may offer greater upside with less risk.

For more investment options, check out 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for the Long Term. No disclosures were made in the article.

Read more at Yahoo Finance: LifeSci Capital Reiterates Buy Rating